Other Consolidated Financial Statement Detail

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Other Consolidated Financial Statement Detail

Supplemental Cash Flow Information

Supplemental disclosure of cash flow information for the years ended December 31, 2020, 2019 and 2018, is as follows:


	For the Years Ended December 31,
(In millions)	2020		2019		2018
Cash paid during the year for:
Interest	$	272.7	$	244.2	$	243.2
Income taxes	906.7		1,064.5		1,007.1

Non-cash Operating, Investing and Financing Activity

In the fourth quarter of 2018 we accrued $300.0 million upon reaching $20.0 billion in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG.

In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately $12.4 million and $50.0 million in our consolidated balance sheets as of December 31, 2020 and 2019, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 10, Property, Plant and Equipment, to these consolidated financial statements.

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:


	For the Years Ended December 31,
(In millions)	2020		2019		2018
Interest income	$	42.0	$	120.0	$	112.5
Interest expense	(222.5)		(187.4)		(200.6)
Gain (loss) on investments, net	685.7		204.7		119.5
Foreign exchange gains (losses), net	(10.7)		(7.0)		(9.9)
Other, net	2.9		(47.0)		(10.5)
Total other income (expense), net	$	497.4	$	83.3	$	11.0

Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.

For the year ended December 31, 2020, net unrealized and realized gains on our holdings in equity securities were approximately $681.8 million and $12.1 million, respectively, compared to net unrealized and realized gains of $150.1 million and $50.0 million in 2019. The net unrealized gains recognized during the year ended December 31, 2020, primarily reflects an increase in the fair value of Denali and Sangamo common stock of approximately $703.9 million.

The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December 31, 2020, 2019 and 2018:


	For the Years Ended December 31,
(In millions)	2020		2019		2018
Net gains (losses) recognized during the period on equity securities	$	693.9	$	200.1	$	127.9
Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions	12.1		50.0		(0.6)
Unrealized gains (losses) recognized during the period on equity securities	$	681.8	$	150.1	$	128.5

Accrued Expenses and Other

Accrued expenses and other consists of the following:


	As of December 31,
(In millions)	2020		2019
Revenue-related reserves for discounts and allowances	$	1,080.6	$	1,001.1
Collaboration expenses	389.9		281.6
Employee compensation and benefits	333.8		309.1
Royalties and licensing fees	218.5		220.9
Derivative liabilities	181.5		6.7
Current portion of contingent consideration obligations	149.6		148.4

Other	791.4		798.0
Total accrued expenses and other	$	3,145.3	$	2,765.8

Other Long-term Liabilities

Other long-term liabilities were $1,329.6 million and $1,348.9 million as of December 31, 2020 and 2019, respectively, and include accrued income taxes totaling $709.9 million and $803.3 million, respectively.